Combination therapy with low doses of ponatinib and steroids in elderly and frail patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

In the GIMEMA LAL1811 trial, including "unfit" patients with newly diagnosed Ph + ALL, 44 patients received 45 mg of ponatinib (PONA) daily with prednisone, and complete hematological remission (CHR) was achieved in 86.4% at 24 weeks. The combination of BCR-ABL tyrosine kinase inhibitors (TKIs) and chemotherapy has significantly improved outcomes among patients with Philadelphia chromosome-positive (Ph +) acute lymphoblastic leukemia (ALL) [[1]]. [Extracted from the article]